-+ 0.00%
-+ 0.00%
-+ 0.00%

SouthState Bank (SSB) Q3 Results Keep Margin Resilience In Focus

Simply Wall St·10/23/2026 01:36:49
语音播报

SouthState Bank stock came into today with only modest recent gains, then jumped 2.4% to about $105 after the market digested its Q3 2026 earnings. The headline result was simple. The bank kept net interest margin at 3.78% while pushing loans and deposits higher at roughly a 9% annualized pace and doing it with net charge-offs running at only 9 basis points.

Short-term traders may focus on the EPS print and the move in the share price. Long-term investors are more likely to weigh this margin resilience and credit profile against multi year earnings forecasts and the current P/E debate.

Love SouthState Bank's stable net interest margin but want a wider set of banks with strong balance sheets and fundamentals? Compare it against our list of solid balance sheet and fundamentals stocks (26 results)

Q3 2026 Earnings Summary

  • Total Revenue (Q3 2026 vs. Q3 2025): US$665.1m vs. US$693.7m (top line lower compared with the prior year)
  • Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$223.8m vs. US$246.6m (profit softened compared with the prior period)
  • Basic EPS (Q3 2026 vs. Q3 2025): US$2.31 vs. US$2.44 (per share earnings lower than a year ago)
  • Net Interest Margin, or NIM (Q3 2026 vs. Q3 2025): 3.78% vs. 4.06% (spread income compressed compared with the prior year)
Earnings only tell part of the story, because cash flows often give you a clearer view of how much investors are really paying for SouthState Bank's underlying business. If you focus on SouthState Bank's cash flows alone, the stock could be a whopping 47% undervalued.
NYSE:SSB Trailing 12-Month Revenue & Expenses Breakdown as at Oct 2026
NYSE:SSB Trailing 12-Month Revenue & Expenses Breakdown as at Oct 2026

SouthState bull case: Texas, fees and tech on trial

Optimists argue that SouthState Bank can keep using its newer markets, extra producers, and AI toolkit to power the business. That ambition is explicit.

"Substantial pipeline increases and ongoing recruitment of revenue producers in high growth markets, including a commercial sales force that expanded more than 10% in three quarters and contributed roughly US$600m of loan production and a US$1.5b pipeline by Q2 2026, point to further growth in revenue and net interest income."

Q3 results broadly track this script. Loan production reached about US$5b for the quarter with loans and deposits both rising at a 9% annualized pace. NIM held at 3.78% and credit losses stayed low, which shows the growth push is not yet eroding asset quality.

SouthState bear case: margin and cost risks under the microscope

The concern is that funding costs and rising expenses eventually overpower the growth story at SouthState Bank.

"Noninterest expense is guided to grow about 4% year over year from a US$1.407b base in 2025, reflecting merit increases and hiring that are only partly offset by higher deferred loan origination costs. If AI initiatives and efficiency efforts do not offset this cost growth as expected, operating leverage could weaken, which would limit any improvement in operating margin and earnings."

Recent numbers keep this risk alive. Noninterest expense reached US$375m in Q3 with management already running ahead of the US$14m full year hiring budget and now expecting US$21m to US$22m. Correspondent and capital markets fees also softened, so operating leverage looks tight despite stable credit.

One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all.

Hunt Quiet Disconnects Before Consensus

SouthState Bank just showed how a single quarter can reset expectations without changing every assumption. The real opportunity could sit in stocks that appear mispriced before markets close that gap.

  • Company 1 - 38% below our estimate - serves merchants by consolidating fragmented local payment rails into one automated cross-border platform for transactions.
  • Company 2 - 23% below our estimate - scales production and access for new cardiometabolic drugs that payers include in long-term chronic care budgets.
  • Company 3 - 17% below our estimate - books multi-year electrical projects that must be completed before hyperscale data centers can activate planned capacity.

Those are three of them. See every one of the 30 undervalued companies on it →